Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial
NCT ID: NCT05314725
Last Updated: 2022-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
24 participants
INTERVENTIONAL
2022-06-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery
NCT00524472
Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery
NCT04284722
Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery
NCT01971047
SGLT2 Inhibitors and Perioperative Period
NCT06326528
Diabetes in the Perioperative Period
NCT00738114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SGLT-2 inhibitor
SGLT2 inhibitor
10 days of SGLT2 inhibitor after surgery
placebo
Placebo
10 days of placebo after surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGLT2 inhibitor
10 days of SGLT2 inhibitor after surgery
Placebo
10 days of placebo after surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least two independent measurements of blood glucose above 7.7mmol/l within the first 48 hours after surgery
* Age of 18 to 85
* Must be able to understand and sign informed content
Exclusion Criteria
* Impaired kidney function (eGFR \< 45mL/min)
* Severe liver disease (defined as transaminases above X 3 normal levels)
* Acute pancreatitis within the last two months or a history of chronic pancreatitis
* Participation in another pharmacological intervention trial
* Predictable poor compliance (for instance mentally impaired)
* Pregnancy or lactation (fertile women must have a negative serum or urine pregnancy test to participate)
* Allergy to study medication
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zealand University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie P Palmgren Colov
Role: PRINCIPAL_INVESTIGATOR
Zealand University Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REG-094-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.